Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial
Abstract
PURPOSE For patients with breast cancer undergoing breast conservation, escalating the dose (boost) of radiation to the lumpectomy cavity after whole-breast irradiation (WBI) reduces ipsilateral breast recurrence (IBR) but extends treatment duration. This phase III trial investigated whether boost delivery during WBI versus after WBI provides noninferior IBR and preserves cosmetic appearance. METHODS NRG/RTOG 1005 randomly assigned patients at higher risk for IBR after lumpectomy and axillary surgery to either a sequential boost of 12 Gy in six fractions(F) or 14 Gy in 7F after WBI of 50 Gy in 25F or 42.7 Gy in 16F (sequential arm) or a concurrent boost of 8 Gy in 15F of 0.53 Gy per day with WBI of 40 Gy in 15F (concurrent arm) using 3-dimensional conformal radiation therapy (RT) or intensity-modulated RT. Based on 1.59% 5-year IBR for the sequential arm, defining the noninferiority margin as a hazard ratio upper limit on the 90% CI of 2.12, 2,312 patients provide 80% power for noninferiority of IBR as first recurrence for the concurrent arm. Secondary end points included disease-free survival and overall survival, adverse events (AEs), and cosmetic outcomes. RESULTS Between May 24, 2011, and June 20, 2014, 2,354 patients were randomly assigned, with 2,255 eligible for analysis (sequential arm, n = 1,118; concurrent arm, n = 1,137). With median follow-up of 7.3 years, there were 56 IBR events; 5- and 7-year IBR were 2.1% and 2.2% on the sequential arm and 1.9% and 2.6% on the concurrent arm, respectively. The noninferiority criterion was met: HR (90% CI): 1.31 (0.84 to 2.04), P = .037. No differences were observed in AEs, cosmetic outcomes, or survival between arms. CONCLUSION Concurrent boost during WBI results in noninferior IBR compared with sequential boost without worsening toxicity or cosmetic outcomes and reduces overall treatment time.
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (25)
Frank A. Vicini
Michigan Healthcare Professionals, Pontiac
Kathryn Winter
NRG Oncology Statistics and Data Management Center, Philadelphia, PA
Gary M. Freedman
University of Pennsylvania/Abramson Cancer Center, Philadelphia, PA
Douglas W. Arthur
Virginia Commonwealth University/Massey Cancer Center, Richmond, VA
Barry S. Rosenstein
Soren M. Bentzen
University of Maryland/Greenebaum Cancer Center, Baltimore, MD
X. Allen Li
Medical College of Wisconsin, Milwaukee
Michele Y. Halyard
Mayo Clinic, Phoenix, AZ
Wendy A. Woodward
Richard J. Bleicher
Fox Chase Cancer Center, Philadelphia, PA
Alphonse Taghian
Massachusetts General Hospital Cancer Center, Boston, MA
Janice Lyons
Case Western Reserve University, Cleveland, OH
Janice K. Tomberlin
Texas Oncology Bedford, Bedford, TX
Samantha A. Seaward
Department of Radiation Oncology, Kaiser Permanente Oncology Clinical Trials, Vallejo, CA
Sally B. Cheston
Central Maryland Radiation Oncology in Howard County, Columbia, MD
Andrew C. Hoover
University of Kansas Cancer Center, Kansas City, KS
Bethany M. Anderson
Francisco E. Perera
Verspeeten Family Cancer Centre, London, ON, Canada
Matthew M. Poppe
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Ivy A. Petersen
Mayo Clinic, Rochester, MN
Sachin Jhawar
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Tarek Hijal
McGill University Health Centre, Montreal, QC, Canada
Jennifer Moughan
Department of Statistics, NRG Oncology Statistics and Data Management Center, Philadelphia, PA
Benjamin Movsas
Julia R. White
University of Kansas Medical Center Comprehensive Cancer Center, Kansas City